{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_codes_comments in Code Comments (approximate match)
Status:
US Approved Rx
(1993)
Source:
BLA103471
(1993)
Source URL:
First approved in 1993
Source:
BLA103471
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03395704: Phase 2 Interventional Completed Hereditary Hemochromatosis
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03938935: Not Applicable Interventional Unknown status Flexor Tendon Repair
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sampeginterferon beta-1a [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04262479: Phase 2 Interventional Completed Latent Autoimmune Diabetes in Adults
(2020)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
